CV Sciences operates two distinct divisions: pharmaceuticals and consumer products. These divisions are supported by our medical and scientific advisory board, and state‐of‐the art production facilities.
Chief Executive Officer
Mr. Dowling was appointed as Chief Executive Officer of the Company in May 2018. Prior to his appointment as CEO, Mr. Dowling held the position of CFO with the Company since 2014. Prior to 2014, Mr. Dowling held numerous senior positions including President and Chief Financial Officer of MediVas, LLC, a biotechnology company focused on drug formulation and delivery from 2005 to 2013 where he led day-to-day operations, drug research and development, product development and commercialization and strategic alliance building including license agreements with Pfizer, Merck, Wyeth, DSM, Guidant and Boston Scientific. Mr. Dowling also served as a Managing Director at Citigroup, a global financial services firm, and earlier in his career served various operating, finance and accounting roles in both public accounting and in the banking industry. Mr. Dowling graduated from University of California, Los Angeles in Economics and is a certified public accountant.
Chief Operating Officer, Co-Founder
Mr. Mona III co-founded CV Sciences in 2012 and has been instrumental in developing the worldwide supply chain for hemp products. Mr. Mona III’s expertise in hemp farming, processing, testing and product development of more than 50 novel hemp-based CBD products has directly led to the Company’s successful consumer products division. Mr. Mona III’s leadership role in the U.S. Hemp Roundtable was critical in advancing the Agriculture Improvement Act of 2018, pivotal legislation better known as the “2018 Farm Bill”, which was signed into law in December 2018. As the Company’s Chief Operating Officer, Mr. Mona III is now leading the next phase of the Company’s global supply chain initiative with commencement of commercial hemp farming in the U.S. Mr. Mona III graduated from the University of San Diego in Business Administration.
Director of CV Sciences
Mr. James A. McNulty, CPA, has served as a Director of CV Sciences, Inc. since January 1, 2016. He is CEO of MYMD Pharmaceuticals, Inc. (development stage pharmaceutical company), and is Chief Financial Officer for Hopkins Capital Group, an affiliation of limited liability companies which engage in venture activities primarily in development of pharmaceuticals. He serves as Chief Financial Officer of Repurposed Therapeutics, Inc., DBA Defender Pharmaceuticals, Inc. Mr. McNulty was Chief Financial Officer of Biodelivery Sciences International, Inc. (NASDAQ: BDSI) from 2000 until his retirement from BDSI in December 2014.
Joseph Maroon, MD, FACS is a board-certified neurosurgeon and Heindl Scholar in neurosciences. He is regarded as a premier specialist in the surgical treatment of injuries and diseases of the brain and spine, particularly with microscopic and minimally invasive procedures. He has published over 270 papers and is on numerous editorial boards. He is consistently listed in America’s Best Doctors and has an international patient clientele. He is the co-developer of ImPACT™ (Immediate Post-Concussion Assessment and Cognitive Testing). Dr. Maroon is also a health and fitness expert and Ironman triathlete. He has written six books including Fish Oil: The Natural Anti-Inflammatory and The Longevity Factor: How Resveratrol and Red Wine Activate Genes for a Longer and Healthier Life. He is president of Inflammation Solutions, LLC, and serves as senior vice-president of the American Academy of Anti-Aging Medicine.